Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pay-for-delay

- PMLiVE

First generic version of Teva’s Copaxone cleared by FDA

Will be marketed as Glatopa by Momenta and Novartis’ Sandoz subsidiary

- PMLiVE

Gilead under fire for Sovaldi anti-diversion policy

Accused as generic versions of the drug start to reach the market

Eli Lilly HQ

German court overturns patent on Lilly blockbuster Alimta

Verdict means Actavis can launch generic after December

- PMLiVE

Brintellix first antidepressant with cognition claim in Europe

Trial found it performed better than Lilly’s rival Cymbalta

France flag

French pharma growth restricted by generics

New analysis finds country’s market value will grow only modestly in the coming years

- PMLiVE

ViiV maintains top spot in reputation survey

But former top-ranked Gilead slides down in PatientView poll of patient groups

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

- PMLiVE

Indian generics firm GVK set to be hit with European sales ban

EU regulator raises concerns on conduct of drug studies in India

- PMLiVE

Regulators to improve cooperation on generic drugs

EMA to spearhead information sharing initiative

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

EU flag

EC: Search for Rasi’s replacement could take six months

Commission tells PMLiVE process could still be impacted by the procedure's complexity

- PMLiVE

Ranbaxy hit with EU import ban on antibiotic

Indian generics firm’s plant ruled in breach of manufacturing rules

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links